About the journal
Acta Pharmaceutica Sinica B is an open-access journal published by Elsevier in Netherlands, publishing in english. It is listed in DOAJ and PUBMED according to the sources read. Declared publication charge: 2,600 USD. Declared review time at DOAJ: 44 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier
- ISSN
- 2211-3835 · 2211-3843
- Country
- Netherlands
- Languages
- english
- Access
- Open access
- Declared publication charge
- 2,600 USD
- Articles in DOAJ
- 2848
- Declared review time
- 44 weeks
- Declared peer-review model
- double_blind
Index listings
- DOAJ · 2013-04-25
- PUBMED · 2012-04-01
- Indexing
- DOAJ · PUBMED
- APC
- 2,600 USD
- Declared review time (DOAJ)
- 44 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
2848
Most recent article
2 months ago
Average review time (journal-declared via DOAJ)
44weeks
Works in OpenAlex
3147
Last recorded publication year
2026
h-index
166
i10-index
1910
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2026-04-27
- Added to DOAJ
- 2013-04-25
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 92%
- ORCID iDs in current deposits
- 78%
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity3
- Alternate titles
- APSB
- Source type
- journal
- NLM unique ID (PubMed)
- 101600560
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Nanoplatforms for cancer theranostics
- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Nanoparticle-Based Drug Delivery
- RNA Interference and Gene Delivery
- RNA Interference and Gene Delivery
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
Show all subjects (50)
- Immunotherapy and Immune Responses
- Immunotherapy and Immune Responses
- Ferroelectric and Negative Capacitance Devices
- Big Data and Digital Economy
- Ferroelectric and Negative Capacitance Devices
- Big Data and Digital Economy
- Computational Drug Discovery Methods
- Computational Drug Discovery Methods
- Immune cells in cancer
- Drug Transport and Resistance Mechanisms
- Immune cells in cancer
- Drug Transport and Resistance Mechanisms
- Autophagy in Disease and Therapy
- Autophagy in Disease and Therapy
- Advanced Drug Delivery Systems
- Extracellular vesicles in disease
- Extracellular vesicles in disease
- Advanced Drug Delivery Systems
- Cancer, Hypoxia, and Metabolism
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Protein Degradation and Inhibitors
- Natural product bioactivities and synthesis
- Natural product bioactivities and synthesis
- Ubiquitin and proteasome pathways
- Ubiquitin and proteasome pathways
- Cancer Research and Treatments
- Cancer Research and Treatments
- Liver Disease Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- interferon and immune responses
- interferon and immune responses
- Monoclonal and Polyclonal Antibodies Research
- RNA modifications and cancer
- RNA modifications and cancer
- Advanced biosensing and bioanalysis techniques
- Monoclonal and Polyclonal Antibodies Research
- Advanced biosensing and bioanalysis techniques
Keywords (DOAJ)
- drug delivery
- nanoparticle therapeutics
- gene delivery
- molecular pharmacology
- pharmacokinetics
- medicinal chemistry
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ